查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566962

人工胰臟设备系统市场：按设备类型、最终用户划分：2024-2033 年全球机会分析与产业预测

Artificial Pancreas Devices Systems Market By Device Type (Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems), By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，人工胰臟装置系统市值为4亿美元，预计2024年至2033年复合年增长率为8.8%，到2033年将达到8亿美元。

人工胰臟装置是医疗设备，旨在维持最佳血糖值。这项医疗技术主要旨在监测和调节糖尿病患者（尤其是第 1 型糖尿病患者）的血糖值。这些设备旨在恢復失去的功能、提高人类表现并提高整体生活品质。

人工胰臟设备系统市场的成长主要是由于全球糖尿病（尤其是 1 型糖尿病）盛行率的惊人增长，以及患者和医疗保健提供者对人工胰臟设备系统益处的认识不断提高而推动的。根据 2021 年第 10 版 IDF 糖尿病图谱的主要发现，大约有 5.37 亿成年人患有糖尿病。预计到 2030 年，这一数字将达到 6.43 亿，到 2045 年将达到 7.83 亿。据报道，2021年约有670万人死于糖尿病。此外，医疗保健支出的增加，尤其是在新兴国家，正在使更多患者能够使用先进的糖尿病管理技术。据同一资讯来源称，2021 年糖尿病导致的医疗保健支出至少为 9,660 亿美元。此外，人工胰臟设备系统与数位健康平台和智慧型手机应用程式的整合将增强病人参与，实现更好的远端监控和管理，并成为市场的关键驱动力。然而，人工胰臟装置系统的高成本限制了市场的成长。此外，大多数国家缺乏足够的医疗保健设施来满足人口的需求，而且访问管道有限，也是市场的主要阻碍因素。相反，感测器技术、胰岛素输送系统和控制演算法的不断改进预计将提高人工胰臟设备系统的性能和可靠性，并在预测期内为全球市场扩张提供利润丰厚的机会。此外，越来越多旨在改善糖尿病护理和管理的倡议正在奖励人工胰腺设备系统的采用。例如，世界卫生组织于 2021 年 4 月推出了倡议。该倡议旨在降低糖尿病的风险，并确保糖尿病患者能够获得负担得起的优质治疗和护理。

人工胰臟设备系统产业分为设备类型、最终用户和地区。按设备类型划分，市场分为阈值暂停设备系统、控制范围 (CTR) 系统和控制目标 (CTT) 系统。依最终使用者分为医院、诊所、居家医疗。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按设备类型划分，阈值暂停设备系统细分市场将在 2023 年占据市场份额。

按最终用户划分，居家照护细分市场将在 2023 年获得最大份额。

按地区划分，2023年北美将占据市场主导地位。

可以自订此报告（需要额外的费用和时间表）

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章人工胰臟设备系统市场：依设备类型

  • 市场概况
  • 阈值暂停装置系统
  • 范围控制 (CTR) 系统
  • 目标控制（CTT）系统

第五章人工胰臟设备系统市场：依最终用户分类

  • 市场概况
  • 医院
  • 诊所
  • 居家医疗

第六章人工胰臟设备系统市场：依地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国人工胰臟装置系统市场
    • 加拿大人工胰臟装置系统市场
    • 墨西哥人工胰臟装置系统市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国人工胰臟装置系统市场
    • 法国人工胰臟装置系统市场
    • 英国人工胰臟装置系统市场
    • 义大利人工胰臟装置系统市场
    • 西班牙人工胰臟装置系统市场
    • 其他欧洲人工胰臟装置系统市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本人工胰臟装置系统市场
    • 中国人工胰臟器材系统市场
    • 澳洲人工胰臟装置系统市场
    • 印度人工胰臟装置系统市场
    • 韩国人工胰臟装置系统市场
    • 其他亚太人工胰臟设备系统市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西人工胰臟装置系统市场
    • 沙乌地阿拉伯人工胰臟装置系统市场
    • 南非人工胰臟装置系统市场
    • 其他拉丁美洲/中东/非洲人工胰臟装置系统市场

第七章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第八章 公司简介

  • Medtronic Plc
  • Bigfoot Biomedical, Inc.
  • Johnson And Johnson
  • Tandem Diabetes Care, Inc.
  • Pancreum, Inc
  • TypeZero Technologies, LLC
  • Beta Bionics, Inc
  • Insulate Corporation
  • Diabeloop
  • Inreda Diabetic
简介目录
Product Code: A324367

The artificial pancreas devices systems market was valued at $0.4 billion in 2023, and is projected to reach $0.8 billion by 2033, growing at a CAGR of 8.8% from 2024 to 2033.

Artificial pancreas device is a medical device that mimics the glucose-regulating function of a healthy pancreas, aiming to maintain optimal blood sugar levels. This medical technology is primarily designed to monitor and regulate blood glucose levels in individuals suffering from diabetes, particularly those with type 1 diabetes. These devices aim to restore lost functions, enhance human capabilities, and improve overall quality of life.

The growth of the artificial pancreas devices systems market is majorly driven by alarming increase in global prevalence of diabetes, particularly type 1 diabetes and rise in awareness among patients and healthcare providers about the benefits of artificial pancreas systems. According to the 2021 key findings of IDF Diabetes Atlas 10th edition, approximately 537 million adults are suffering diabetes. This number is estimated to reach 643 million by 2030 and 783 million by 2045. Around 6.7 million deaths were reported due to diabetes in 2021. Moreover, increase in healthcare expenditure, particularly in emerging economies, allows more patients to access advanced diabetes management technologies. As per the same source, diabetes was responsible for at least $966 billion dollars in health expenditure in 2021. Furthermore, the integration of artificial pancreas devices systems with digital health platforms and smartphone applications enhances patient engagement and allows for better remote monitoring and management, which acts as the key driving force of the market. However, high cost associated with the artificial pancreas devices systems restrains the growth of the market. Moreover, lack of appropriate health facilities to meet population needs in most countries and limited access act as the key deterrent factors of the market. On the contrary, continuous improvements in sensor technology, insulin delivery systems, and control algorithms enhance the performance and reliability of artificial pancreas systems, which are expected to offer remunerative opportunities for the expansion of the global market during the forecast period. In addition, increase in initiatives aimed at improving diabetes care and management are providing incentives for the adoption of artificial pancreas systems. For instance, the World Health Organization launched an initiative in April 2021, WHO Global Diabetes Compact. The initiative aims to reduce the risk of diabetes and ensure that diabetic individuals have access to affordable and quality treatment and care.

The artificial pancreas devices systems industry is segmented into device type, end user, and region. By device type, the market is divided into threshold suspend device systems, control-to-range (CTR) systems, and control-to-target (CTT) systems. On the basis of end user, it is divided into hospitals, clinics, homecare. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By device type, the threshold suspend device systems segment dominated the market, in terms of share, in 2023.

Depending on end user, the homecare segment captured the largest share in 2023.

Region wise, North America holds a dominant position in the market in 2023.

Competition Analysis

Competitive analysis and profiles of the major players in the global artificial pancreas devices systems market include Medtronic plc, Bigfoot Biomedical, Inc., Johnson & Johnson, Tandem Diabetes Care, Inc., Pancreum, Inc, TypeZero Technologies, LLC, Beta Bionics, Inc, Insulate Corporation, Diabeloop, and Inreda Diabetic. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Device Type

  • Threshold Suspend Device Systems
  • Control-To-Range (CTR) Systems
  • Control-To-Target (CTT) Systems

By End User

  • Hospitals
  • Clinics
  • Homecare

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Medtronic plc
    • Bigfoot Biomedical, Inc.
    • Johnson & Johnson
    • Tandem Diabetes Care, Inc.
    • Pancreum, Inc
    • TypeZero Technologies, LLC
    • Beta Bionics, Inc
    • Insulate Corporation
    • Diabeloop
    • Inreda Diabetic

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY DEVICE TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Device Type
  • 4.2. Threshold Suspend Device Systems
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Control-To-Range (CTR) Systems
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Control-To-Target (CTT) Systems
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Clinics
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Homecare
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Device Type
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Artificial Pancreas Devices Systems Market
      • 6.2.5.1. Market Size and Forecast, By Device Type
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Artificial Pancreas Devices Systems Market
      • 6.2.6.1. Market Size and Forecast, By Device Type
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Artificial Pancreas Devices Systems Market
      • 6.2.7.1. Market Size and Forecast, By Device Type
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Device Type
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Artificial Pancreas Devices Systems Market
      • 6.3.5.1. Market Size and Forecast, By Device Type
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Artificial Pancreas Devices Systems Market
      • 6.3.6.1. Market Size and Forecast, By Device Type
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Artificial Pancreas Devices Systems Market
      • 6.3.7.1. Market Size and Forecast, By Device Type
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Artificial Pancreas Devices Systems Market
      • 6.3.8.1. Market Size and Forecast, By Device Type
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Artificial Pancreas Devices Systems Market
      • 6.3.9.1. Market Size and Forecast, By Device Type
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Artificial Pancreas Devices Systems Market
      • 6.3.10.1. Market Size and Forecast, By Device Type
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Device Type
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Artificial Pancreas Devices Systems Market
      • 6.4.5.1. Market Size and Forecast, By Device Type
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Artificial Pancreas Devices Systems Market
      • 6.4.6.1. Market Size and Forecast, By Device Type
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Artificial Pancreas Devices Systems Market
      • 6.4.7.1. Market Size and Forecast, By Device Type
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Artificial Pancreas Devices Systems Market
      • 6.4.8.1. Market Size and Forecast, By Device Type
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Artificial Pancreas Devices Systems Market
      • 6.4.9.1. Market Size and Forecast, By Device Type
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Artificial Pancreas Devices Systems Market
      • 6.4.10.1. Market Size and Forecast, By Device Type
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Device Type
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Artificial Pancreas Devices Systems Market
      • 6.5.5.1. Market Size and Forecast, By Device Type
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Artificial Pancreas Devices Systems Market
      • 6.5.6.1. Market Size and Forecast, By Device Type
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Artificial Pancreas Devices Systems Market
      • 6.5.7.1. Market Size and Forecast, By Device Type
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Artificial Pancreas Devices Systems Market
      • 6.5.8.1. Market Size and Forecast, By Device Type
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Medtronic Plc
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Bigfoot Biomedical, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Johnson And Johnson
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Tandem Diabetes Care, Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Pancreum, Inc
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. TypeZero Technologies, LLC
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Beta Bionics, Inc
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Insulate Corporation
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Diabeloop
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Inreda Diabetic
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments